18-19 novembre 2022
CONGRESSO ATBV 2022
Filmati dei lavori
I giornata
ABOVE AND BEYOND LDL CHOLESTEROL
Gaetano Maria De Ferrari, Maddalena Lettino
Optimal Use of Statins, Ezetimibe, and Bempedoic Acid in Clinical Practice – Paolo Calabrò
Evolutions of PCSK9 Inhibition – Giuseppe Musumeci
Icosapent ethyl is different than PolyUnsaturated Fatty Acids: Understanding REDUCE IT – Giuseppe Patti
The future is now: Lipoprotein (a) inhibition and more! – Alberico Catapano
Discussion and Take Home Messages
JOINT ATBV-ACVC SESSION: MANAGEMENT OF ANTITHROMBOTHIC
THERAPY IN CRITICALLY ILL PATIENTS
Ingo Ahrens, Maddalena Lettino
Antithrombothic Strategies in Patients with Mechanical Circulatory Support – Christophe Vendenbriele
Atrial Fibrillation in Critically Ill Patients – Kurt Huber
SPOTLIGHT SESSION: ESTABLISHED AND EMERGING PARENTERAL
ANTIPLATELET AGENTS
Alberto Menozzi, Raffaele Piccolo
Cangrelor and Glycoprotein IIb/IIIa Inhibitors: Different Drugs, Different Roles – Leonardo De Luca
Future Pre-Hospital Strategies: Selatogrel and RUC-4 – Felice Gragnano
II giornata
EVOLVING ANTITHROMBOTIC STRATEGIES IN PATIENTS WITH
ACUTE AND CHRONIC CORONARY SYNDROME: TOWARD
PERSONALIZED MEDICINE?
Claudio Fresco, Luigi Oltrona Visconti
Is Guided Antiplatelet Therapy Ready for Prime Time? – Davide Capodanno
Indication and Timing of P2Y12 Inhibitors Monotherapy After ACS – Leonardo Bolognese
Vascular dose of rivaroxaban: from evidence to pratcice – Marco Ferlini
Bridgining Antithrombothic Strategies in Patients with Coronary Stent Requiring Surgery – Giuseppe Musumeci